Celularity, Inc. (CELU)
1.88
+0.02
(+1.08%)
USD |
NASDAQ |
Sep 03, 13:40
Celularity Research and Development Expense (TTM) : 9.222M for Dec. 31, 2025
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| December 31, 2025 | 9.222M |
| September 30, 2025 | 9.63M |
| June 30, 2025 | 8.876M |
| March 31, 2025 | 9.246M |
| December 31, 2024 | 11.22M |
| September 30, 2024 | |
| June 30, 2024 | |
| March 31, 2024 | |
| December 31, 2023 | |
| September 30, 2023 | 34.45M |
| Date | Value |
|---|---|
| June 30, 2023 | 49.57M |
| March 31, 2023 | 66.32M |
| December 31, 2022 | 71.12M |
| September 30, 2022 | 84.65M |
| June 30, 2022 | 88.11M |
| March 31, 2022 | 86.06M |
| December 31, 2021 | 81.73M |
| September 30, 2021 | 71.74M |
| June 30, 2021 | 59.47M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Tenax Therapeutics, Inc. | 45.26M |
| Manhattan Scientifics, Inc. | -- |
| Exicure, Inc. | 2.029M |
| Century Therapeutics, Inc. | 66.62M |
| Absci Corp. | 86.49M |